Drug Search Results
More Filters [+]

TQ-B3234

Alternative Names: tq-b3234, tqb3234, tq b3234
Latest Update: 2021-11-04
Latest Update Note: Clinical Trial Update

Product Description

Zhengda Tianqing Pharmaceutical Group/Sailing Pharmaceutical Technology/Zhengda Tianqing Pharmaceutical Group is developing tq-b3234, an Oral MEK1 Inhibitor,MEK2 Inhibitor for Advanced Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02996838)

Mechanisms of Action: MEK1 Inhibitor,MEK2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TQ-B3234

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Neurofibroma|Neurofibromatoses|Neurofibromatosis 1

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TQ-B3234-I-02

P1

Not yet recruiting

Neurofibromatosis 1|Neurofibromatoses

2023-12-01

40%

CTR20212106

P1

Recruiting

Neurofibroma

None

Recent News Events

Date

Type

Title